Zoledronate Sequential Therapy After Denosumab Discontinuation to Prevent Bone Mineral Density Reduction

Discontinuation of denosumab without transitioning to another antiresorptive agent results in rapid bone loss and an increased risk of fracture. Previous randomized studies reported inconsistent results regarding the efficacy of zoledronate as sequential therapy.